Business Description
HUTCHMED (China) Limited is a Hong Kong-based biopharmaceutical company founded in 2000 that researches and brings to market treatments for cancer and immune system diseases across global markets. The company has built a broad portfolio of medicines targeting a wide range of conditions, including colorectal, lung, gastric, and kidney cancers, as well as blood disorders such as leukemia and lymphoma. Several of its drugs are already approved and in use, while others are progressing through clinical trials. HUTCHMED works alongside major pharmaceutical partners including AstraZeneca, Lilly, and Takeda to advance its pipeline.
